Market Cap 2.09B P/E - EPS this Y -6.40% Ern Qtrly Grth -
Income -124.94M Forward P/E -12.43 EPS next Y 5.00% 50D Avg Chg 25.00%
Sales 53.52M PEG -0.44 EPS past 5Y - 200D Avg Chg 100.00%
Dividend N/A Price/Book 61.83 EPS next 5Y 19.90% 52W High Chg -8.00%
Recommedations 2.10 Quick Ratio 1.33 Shares Outst. 176.57M 52W Low Chg 647.00%
Insider Own 0.85% ROA -57.39% Shares Float 153.41M Beta 2.79
Inst Own 73.95% ROE - Short Shares 0 Price 11.81
Gross Margin -121.50% Profit Margin -233.45% Avg. Volume 8,490,745 Target Price 11.88
Oper. Margin -228.81% Earnings Feb 25 Volume 4,841,720 Change 6.49%
BioCryst Pharmaceuticals, Inc. News
07:00 AM BioCryst Reports Fourth Quarter and Full Year 2020 Financial Results and Upcoming Key Milestones
06:30 AM BioCryst Pharmaceuticals, Inc. to Host Earnings Call
02/18/21 BioCryst to Present at Upcoming Investor Conferences
02/11/21 BioCryst to Report Fourth Quarter and Full Year 2020 Financial Results on February 25
02/09/21 BioCryst to Present Data at 2021 American Academy of Allergy, Asthma & Immunology Annual Meeting
02/08/21 10 Best Small-Cap Biotech Stocks Under $10 in 2021
02/07/21 What Kind Of Shareholders Hold The Majority In BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares?
02/03/21 BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older
02/02/21 The GameStop frenzy convinced more people to search 'how to buy stocks' than last year's surge
02/02/21 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/01/21 Reddit Traders Declare ‘BioWar’ as Shorted Biotechs Soar
01/28/21 Implied Volatility Surging for BioCryst (BCRX) Stock Options
09:28 AM BioCryst (BCRX) Wins Japanese Approval for HAE Drug Orladeyo
01/22/21 Looking Into Biocryst Pharmaceuticals's Return On Capital Employed
01/22/21 BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema
01/06/21 BioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference
12/23/20 Biotech Stock Roundup: PFE/BNTX Vaccine Authorized in Europe, Updates From AMGN, & More
12/23/20 BioCryst (BCRX) Provides Updates on Galidesivir, Shares Fall
12/23/20 2 Ultra-High-Growth Healthcare Stocks That Are Just Getting Started

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

BCRX Chatroom

User Image Tiger10 Posted - 9 seconds ago

$BCRX "In the launch period for ORLADEYO, the company is not providing specific revenue or operating expense guidance. Based on our expectations for revenue, operating expenses, and our option to access an additional $75 million from our existing credit facility, we believe our current cash runway takes us into 2023." They are going to be tight-lipped, but their cash-position is quite re-assuring. Take advantage today!

User Image Startupenthusiast24 Posted - 16 seconds ago

$BCRX the only surprising "negative" news here is that we only get 20%-40% of the Japanese market.

User Image Gliding Posted - 34 seconds ago

$BCRX rest in piece... just woke up to this awful news

User Image rick75 Posted - 48 seconds ago

$BCRX But, but, but... GALIDESIVIR is dead....??? 😳💥 "Research and development (R&D) expenses for the fourth quarter of 2020 increased to $35.4 million from $26.8 million in the fourth quarter of 2019, primarily due to increased investment in our Factor D and galidesivir programs"

User Image HiddenHarmonizer Posted - 59 seconds ago

$BCRX Bye day traders, thanks for visiting.

User Image dwarfofcoolstreet Posted - 1 minute ago

$BCRX

User Image traderjer Posted - 1 minute ago

$BCRX Cask strength earnings (no dilution in sight).

User Image Swiftytwits Posted - 2 minutes ago

$BCRX about so basically, EU approval can come anytime after March 12th. Which, since is already used for compassionate reasons there, id assume it comes by end of march possibly

User Image Sprackillac Posted - 2 minutes ago

$BCRX where is that saffron guy/girl. Need a soft bash post right now then this thing will start flying.

User Image Money_Mane Posted - 3 minutes ago

$BCRX I will be buying more today if it’s still red after the conference. You lucky pre market mutha ffffff

User Image smmajmoney Posted - 3 minutes ago

$BCRX solid report. Only disappointment is sales of orladeyo. No doubt they’ll come. No reason to sell and all the reasons to buy any significant dip.

User Image buythedipsoon Posted - 3 minutes ago

$BCRX Looking for a great earnings report this morning. They moved it up early for a reason. I’m long on this stock.

User Image kennyboyvegas Posted - 4 minutes ago

$BCRX the street can’t see past it’s own nose most of the time, so nothing surprising. Back up next week.

User Image MITornado Posted - 4 minutes ago

$BCRX $20 March options, starting to think someone knew Factor D data wouldn’t be released until 3/22. . Expecting a big run up to data. 🧐

User Image justfkntrade Posted - 4 minutes ago

$BCRX if you were expecting a massive earnings, are the type to set stop losses or bail early because of one quarter not having terrific earnings, then you simply do not belong here.

User Image todroddee Posted - 4 minutes ago

$BCRX Factor D slide about no serious adverse events and no ekg or lab issues puts bcx9930 light years ahead of its competition, alxn2050 which is still just starting its trials looking at healthy patients with ekg changes. There’s a lot of data right there even before March 22nd. Also, interesting no galidesivir update but they burned some of their own R&D cash to study it. They may have independently funded the remainder of their covid study to complete it secretly.

User Image dwarfofcoolstreet Posted - 4 minutes ago

$BCRX days remaining until the D

User Image sudokujesus Posted - 5 minutes ago

$BCRX @ThirdEyeHoldings lol at those options being exercised being a clear indication of where this is going. like i said, short term negative. why sell the day before the ER if the ER is going to contain news that drives the price up. could have just as easily scheduled this earnings report 3 days ago, but they didn’t. and you never questioned why. i remain long term bullish but holy cow you really gotta learn how to read the tea leaves or at least grasp common sense when it is put right in front of you.

User Image Ninety9Percent Posted - 6 minutes ago

$BCRX Can't imagine we don't see a huge short attack today. Or several. I'm fixing to lock in losses in other places to snatch up the gifts here.

User Image ScaldedDog Posted - 6 minutes ago

$BCRX Hilarious. That dip and all others will be eaten up like a fat man at a smorgasbord.

User Image Adeas1965 Posted - 6 minutes ago

$BCRX It was never about this ER grow some or go some.

User Image Startupenthusiast24 Posted - 6 minutes ago

$BCRX main points from release. Good news all around:

User Image Sprackillac Posted - 6 minutes ago

$BCRX i have a feeling there is going to be some big upward momentum going into the 22nd.

User Image SleeplessSEA Posted - 6 minutes ago

$BCRX Honestly, I sort of feel bad snatching someone's 2k shares at 10.55 a few minutes ago... unless it's from a bear...I felt like took a candy from a baby...

User Image Swiftytwits Posted - 7 minutes ago

$BCRX you guys dont fall for the bs. 6k vol and you idiots are getting played by manipulation in pm😂😂😂😂😂

User Image LTtrader04 Posted - 7 minutes ago

$BCRX who sold at 10.5. Lol

User Image Hazedddd Posted - 7 minutes ago

$BCRX honestly tho, they literally told us there will be NO Q4 REVENUE! But some people are shocked and sell when there's no revenue You couldn't make this shit up Anyway if its dragged round $10 I'll slap it

User Image Imgreat Posted - 7 minutes ago

$BCRX so BCRX had orlayedo approved and bought a sales team in December, end of their quarter. So people shouldn't be surprised they didn't have a lot of profits. That should start next quarter but it will be great if they let us know how many prescriptions they have received during the conference call.

User Image fridge987 Posted - 8 minutes ago

$BCRX Lesson this morning is how day traders lose their money when they know nothing about a company but come in for a quick play on earnings and update and then get scared by a falling share price and sell. See ya!

User Image ChartMill Posted - 8 minutes ago

$BCRX was analyzed by 9 analysts. The buy consensus is at 91%. So analysts seem to be very confident about $BCRX. https://www.chartmill.com/stock/analyzer/stock/BCRX?view=analyst-ratings&utm_source=stocktwits&utm_medium=ANALYST&utm_content=BCRX&utm_campaign=social_tracking

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own
Barnes Alane P Senior VP, Ch.. Senior VP, Chief Legal Officer Dec 15, 5:35 PM Option 4.15 13,741 57,025 121,802